PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. 

 

Learn more About PAION

Our Mission

PAION’s mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare. 

PAION's Strategy & Partnering

AR 2020

Teleconference & webcast

31 March 2021

Replay

news

07/16/2021

PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY...

DGAP-News: PAION AG / Key word(s): Product Launch 16.07.2021 /...

Read more
07/09/2021

​​​​​​​PAION ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG APPLICATION FOR...

DGAP-News: PAION AG / Key word(s): Regulatory Admission...

Read more
06/29/2021

PAION RECEIVES UK MHRA APPROVAL OF BYFAVO (REMIMAZOLAM) FOR PROCEDURAL SEDATION

DGAP-News: PAION AG / Key word(s): Regulatory Approval 29.06.2021...

Read more

PAION Chart

Load Chart

I consent to the display of external content. This enables personal data to be transmitted to third-party platforms. Read more about our privacy policy.